3 results
Approved WMOPending
To investigate what the ideal moment to vaccinate would be, early (after 2-6 months) or late (after 9-12 months) after cessation of rituximab. Secondly to study the immune-response to vaccination with influenza virus vaccine after treatment with…
Approved WMORecruiting
The overall aim of this study is to demonstrate increase of tumor-infiltrating CD8+ T cells in non-small cell lung cancer during neo-adjuvant treatment with durvalumab (MEDI4736).
Approved WMOWill not start
To compare the number of responders to vaccination with the influenza virus vaccine and pneumococcal vaccine at different time points in treatment cycle of lenalidomide. Secondly to study the immune-response to vaccination, during treatment with…